The effect of statin treatment on inflammation in patients with metabolic syndrome;Metabolik sendromlu hastalarda statin tedavisinin inflamasyon iizerine etkisi

Turk Kardiyoloji Dernegi Arsivi

Volumn 37, Issue 1, 2009, Pages 26-34

  Aydin, Mustafa ^a   Onuk, Tolga ^a   Doǧan, Sait Mesut ^a   Yildirim, Nesligül ^a   Demirci, Erkan ^a   Kalayciog̈lu, Ezgi ^a   Madak, Hediye ^a   Aktop, Ziyaettin ^a   Çetiner, Mehmet Ali ^a   Sayin, Muhammet Raşit ^a   Karaasian, Sibel ^a  

^a Zonguldak Karaelmas Universitesi Tip Fakultesi   (Turkey)

Author keywords

Anticholesteremic agents therapeutic use; Antigens; Biological markers; Blood platelets; Cell adhesion molecules; Flow cytometry; Leukocytes; Metabolic syndrome X; Monocytes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD63 ANTIGEN; CD8 ANTIGEN; CHOLESTEROL; CREATINE KINASE; FLUINDOSTATIN; GLYCOPROTEIN P 15095; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; GRANULOCYTE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LEUKOCYTE; LYMPHOCYTE COUNT; MALE; METABOLIC SYNDROME X; MONOCYTE; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIGENS, CD; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, LDL; FATTY ACIDS, MONOUNSATURATED; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INFLAMMATION; INSULIN RESISTANCE; LYMPHOCYTE COUNT; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TRIGLYCERIDES;

EID: 67249091315     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
2. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999;22 Suppl 3:C25-30.
3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
4. Onat A, Sansoy V. Metabolic syndrome, major culprit of coronary disease among Turks: its prevalence and impact on coronary risk. [Article in Turkish] Türk Kardiyol Dern Arş 2002;30:8-15.
5. Onat A. Erişkinlerimizde kalp hastahklari prevalansi, yeni koroner olaylar ve kalpten ölüm sikhǧi. In: Onat A, editör. TEKHARF, Yüzyil dönümünde Türk erişkin koroner risk haritasi ve koroner kalp hastahǧi. İstanbul: Mas Matbaacilik; 2001, s. 17-26.
6. Onat A, Ceyhan K, Sansoy V, Keleş İ, Erer B, Uysal Ö. Erişkinlerimizin yarisinda bulunan dislipidemi ve metabolik sendromun özellikleri ve kombine hiperlipidemi ile ilişkisi: ayni zamanda plazma trigliserid düzeyi üst siniri konusunda bir katki. Türk Kardiyol Dern Arş 2001;29:274-85.
7. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 2001;19:523-8.
8. Damci T. Sendrom X. İlkova H, editör. Diabet, obezite ve metabolizma hastaliklari. Istanbul: İ. Ü. Cerrahpaşa Tip Fakültesi Sürekli Tip Eǧitimi Komisyonu; Yayin No: 20; 2000. p. 129-31.
9. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348:1339-42.
10. Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rochen J, et al. Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 1997;80:287-93.
11. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-41.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
13. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
15. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999;41:402-17.
16. Nègre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997;1345:259-68.
17. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50.
18. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003;139:97-104.
19. van Nieuw Amerongen GP, Vermeer MA, Nègre-Aminou P, Lankelma J, Emeis JJ, van Hinsbergh VW. Simvastatin improves disturbed endothelial barrier function. Circulation 2000;102:2803-9.
20. Undas A, Brozek J, Musial J. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab 2002;48:287-96.
21. Humphries KH, Lee M, Sheldon R, Ramanathan K, Dorian P, Green M, et al. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 2007;154:908-13.
22. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007;49:290-7.
23. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-7.
24. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
25. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
26. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
27. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
28. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
29. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999;353:118-9.
30. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. Lancet 1999;353:1274.
31. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adi-ponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism. 2007;56:491-6.
32. Cronstein BN, Weismann G. The adhesion molecules of inflammation. Arthritis Rheum 1993;36: 147-57.
33. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60:577-84.
34. Arteaga RB, Chirinos JA, Soriano AO, Jy W, Horstman L, Jimenez JJ, et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 2006;98:70-4.
35. Jy W, Minagar A, Jimenez JJ, Sheremata WA, Mauro LM, Horstman LL, et al. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis. Front Biosci 2004;9:3137-44.
36. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 2OO7;153:881-8.
37. Serrano CV Jr, Yoshida VM, Venturinelli ML, D'Amico E, Monteiro HP, Ramires JA, et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis 2001; 157:505-12.
38. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-7.